There has been a broker report of reasonable off label usage in...

There has been a broker report of reasonable off label usage in the US markets. The view was that dose sales may be impacted due to the trial not yielding the desired result for overall PFS at 1st line.

As far as I can determine SIRT can be used in the CE markets as DRs see fit, but the US market is labelled for 3rd line usage in mCRC.

I had previously assumed from reading the report (yes I know making an ass out of myself) that the off-label usage in the US implied usage for mCRC at 1st line.

My latest view is that there has been very little 1st line usage (outside of the trial) and the off-label usage has been for other cancers - e.g. HCC.

I have conflicting data and wanted to survey anyone who has data on this subject area. Apparently there is data in the PD, but my searches have not yielded anywhere near the sorts of numbers that my initial information suggests.

I'm looking for referable data, or medco experiences in the US - please.